Literature DB >> 26445996

Molecular pathological epidemiology gives clues to paradoxical findings.

Reiko Nishihara1,2,3, Tyler J VanderWeele4,5, Kenji Shibuya6, Murray A Mittleman4,7, Molin Wang4,5,8, Alison E Field4,8,9,10, Edward Giovannucci11,4,8, Paul Lochhead12, Shuji Ogino13,14,15.   

Abstract

A number of epidemiologic studies have described what appear to be paradoxical associations, where an incongruous relationship is observed between a certain well-established risk factor for disease incidence and favorable clinical outcome among patients with that disease. For example, the "obesity paradox" represents the association between obesity and better survival among patients with a certain disease such as coronary heart disease. Paradoxical observations cause vexing clinical and public health problems as they raise questions on causal relationships and hinder the development of effective interventions. Compelling evidence indicates that pathogenic processes encompass molecular alterations within cells and the microenvironment, influenced by various exogenous and endogenous exposures, and that interpersonal heterogeneity in molecular pathology and pathophysiology exists among patients with any given disease. In this article, we introduce methods of the emerging integrative interdisciplinary field of molecular pathological epidemiology (MPE), which is founded on the unique disease principle and disease continuum theory. We analyze and decipher apparent paradoxical findings, utilizing the MPE approach and available literature data on tumor somatic genetic and epigenetic characteristics. Through our analyses in colorectal cancer, renal cell carcinoma, and glioblastoma (malignant brain tumor), we can readily explain paradoxical associations between disease risk factors and better prognosis among disease patients. The MPE paradigm and approach can be applied to not only neoplasms but also various non-neoplastic diseases where there exists indisputable ubiquitous heterogeneity of pathogenesis and molecular pathology. The MPE paradigm including consideration of disease heterogeneity plays an essential role in advancements of precision medicine and public health.

Entities:  

Keywords:  Bias; Cardiovascular disease; Molecular diagnostics; Multifactorial diseases; Personalized medicine

Mesh:

Year:  2015        PMID: 26445996      PMCID: PMC4639412          DOI: 10.1007/s10654-015-0088-4

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  80 in total

1.  Public Health in the Precision-Medicine Era.

Authors:  Ronald Bayer; Sandro Galea
Journal:  N Engl J Med       Date:  2015-08-06       Impact factor: 91.245

2.  Association of the colorectal CpG island methylator phenotype with molecular features, risk factors, and family history.

Authors:  Daniel J Weisenberger; A Joan Levine; Tiffany I Long; Daniel D Buchanan; Rhiannon Walters; Mark Clendenning; Christophe Rosty; Amit D Joshi; Mariana C Stern; Loic LeMarchand; Noralane M Lindor; Darshana Daftary; Steven Gallinger; Teresa Selander; Bharati Bapat; Polly A Newcomb; Peter T Campbell; Graham Casey; Dennis J Ahnen; John A Baron; Robert W Haile; John L Hopper; Joanne P Young; Peter W Laird; Kimberly D Siegmund
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01-13       Impact factor: 4.254

3.  Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer.

Authors:  Wade S Samowitz; Hans Albertsen; Carol Sweeney; Jennifer Herrick; Bette J Caan; Kristin E Anderson; Roger K Wolff; Martha L Slattery
Journal:  J Natl Cancer Inst       Date:  2006-12-06       Impact factor: 13.506

4.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

5.  Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status.

Authors:  Mingyang Song; Reiko Nishihara; Molin Wang; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Kana Wu; Shuji Ogino; Zhi Rong Qian; Kentaro Inamura; Xuehong Zhang; Kimmie Ng; Sun A Kim; Kosuke Mima; Yasutaka Sukawa; Katsuhiko Nosho
Journal:  Gut       Date:  2015-01-15       Impact factor: 23.059

6.  A nearly unavoidable mechanism for collider bias with index-event studies.

Authors:  W Dana Flanders; Ronald C Eldridge; William McClellan
Journal:  Epidemiology       Date:  2014-09       Impact factor: 4.822

7.  MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.

Authors:  Nicholas J Hawkins; James H-F Lee; Justin J-L Wong; Chau-To Kwok; Robyn L Ward; Megan P Hitchins
Journal:  Mod Pathol       Date:  2009-09-04       Impact factor: 7.842

8.  Biomarkers in precision therapy in colorectal cancer.

Authors:  Marlies S Reimers; Eliane C M Zeestraten; Peter J K Kuppen; Gerrit Jan Liefers; Cornelis J H van de Velde
Journal:  Gastroenterol Rep (Oxf)       Date:  2013-08-23

Review 9.  Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis.

Authors:  Katherine M Flegal; Brian K Kit; Heather Orpana; Barry I Graubard
Journal:  JAMA       Date:  2013-01-02       Impact factor: 56.272

10.  Epigenetics and colorectal cancer pathogenesis.

Authors:  Kankana Bardhan; Kebin Liu
Journal:  Cancers (Basel)       Date:  2013-06-05       Impact factor: 6.639

View more
  24 in total

1.  Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Authors:  Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino
Journal:  J Clin Oncol       Date:  2017-04-13       Impact factor: 44.544

Review 2.  Integration of microbiology, molecular pathology, and epidemiology: a new paradigm to explore the pathogenesis of microbiome-driven neoplasms.

Authors:  Tsuyoshi Hamada; Jonathan A Nowak; Danny A Milner; Mingyang Song; Shuji Ogino
Journal:  J Pathol       Date:  2019-02-20       Impact factor: 7.996

Review 3.  Molecular pathological epidemiology: new developing frontiers of big data science to study etiologies and pathogenesis.

Authors:  Tsuyoshi Hamada; NaNa Keum; Reiko Nishihara; Shuji Ogino
Journal:  J Gastroenterol       Date:  2016-10-13       Impact factor: 7.527

Review 4.  Vitamin D and colorectal cancer: molecular, epidemiological and clinical evidence.

Authors:  Ruoxu Dou; Kimmie Ng; Edward L Giovannucci; JoAnn E Manson; Zhi Rong Qian; Shuji Ogino
Journal:  Br J Nutr       Date:  2016-05       Impact factor: 3.718

5.  Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Authors:  Laurence Albiges; A Ari Hakimi; Wanling Xie; Rana R McKay; Ronit Simantov; Xun Lin; Jae-Lyun Lee; Brian I Rini; Sandy Srinivas; Georg A Bjarnason; Scott Ernst; Lori A Wood; Ulka N Vaishamayan; Sun-Young Rha; Neeraj Agarwal; Takeshi Yuasa; Sumanta K Pal; Aristotelis Bamias; Emily C Zabor; Anders J Skanderup; Helena Furberg; Andre P Fay; Guillermo de Velasco; Mark A Preston; Kathryn M Wilson; Eunyoung Cho; David F McDermott; Sabina Signoretti; Daniel Y C Heng; Toni K Choueiri
Journal:  J Clin Oncol       Date:  2016-10-20       Impact factor: 44.544

Review 6.  Staphylococcus aureus in the Intensive Care Unit: Are These Golden Grapes Ripe for a New Approach?

Authors:  Georgia R Sampedro; Juliane Bubeck Wardenburg
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

7.  The Rotterdam Study: 2018 update on objectives, design and main results.

Authors:  M Arfan Ikram; Guy G O Brusselle; Sarwa Darwish Murad; Cornelia M van Duijn; Oscar H Franco; André Goedegebure; Caroline C W Klaver; Tamar E C Nijsten; Robin P Peeters; Bruno H Stricker; Henning Tiemeier; André G Uitterlinden; Meike W Vernooij; Albert Hofman
Journal:  Eur J Epidemiol       Date:  2017-10-24       Impact factor: 8.082

Review 8.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

9.  Cancer subtypes in aetiological research.

Authors:  Lorenzo Richiardi; Francesco Barone-Adesi; Neil Pearce
Journal:  Eur J Epidemiol       Date:  2017-05-11       Impact factor: 8.082

10.  Body mass index and risk of colorectal carcinoma subtypes classified by tumor differentiation status.

Authors:  Akiko Hanyuda; Yin Cao; Tsuyoshi Hamada; Jonathan A Nowak; Zhi Rong Qian; Yohei Masugi; Annacarolina da Silva; Li Liu; Keisuke Kosumi; Thing Rinda Soong; Iny Jhun; Kana Wu; Xuehong Zhang; Mingyang Song; Jeffrey A Meyerhardt; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino; Reiko Nishihara
Journal:  Eur J Epidemiol       Date:  2017-05-16       Impact factor: 8.082

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.